Once processed and packaged, these compounds are transported out of the liver either through the kidneys into urine or through bile into the digestive tract
Results can vary
[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity
Available from: Next scheduled review date: 6 July 2029 More on this topic What Is Off-Label Prescribing
This innovative formula uses nanotechnology for enhanced absorption and efficient delivery of glutathione to your cells
Our team is ready to support you on your journey.